These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38411622)

  • 21. Oral antivirals for COVID-19 among patients with cancer.
    Guermazi D; Arvanitis P; Vieira K; Warner JL; Farmakiotis D
    Support Care Cancer; 2024 Jul; 32(8):496. PubMed ID: 38980433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.
    Arbel R; Wolff Sagy Y; Hoshen M; Battat E; Lavie G; Sergienko R; Friger M; Waxman JG; Dagan N; Balicer R; Ben-Shlomo Y; Peretz A; Yaron S; Serby D; Hammerman A; Netzer D
    N Engl J Med; 2022 Sep; 387(9):790-798. PubMed ID: 36001529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19.
    Camp D; Caputo M; Echevarria FM; Achenbach CJ
    BMC Infect Dis; 2024 Sep; 24(1):963. PubMed ID: 39266964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia.
    Yii YC; Shih HM; Chen CL; Lai ZL; Hsu YL; Lai CH; Hsueh PR; Cho DY
    Int J Antimicrob Agents; 2024 Jan; 63(1):107020. PubMed ID: 37898365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Utility Model of Nirmatrelvir/Ritonavir in Brazil: Analysis of a Vaccinated Population.
    Fernandes RRA; Barros BM; da Costa MR; Magliano CAS; Tura BR; Morais QCD; Santos M
    Value Health Reg Issues; 2024 Mar; 40():74-80. PubMed ID: 37995417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
    Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
    J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
    N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiviral pills could change pandemic's course.
    Couzin-Frankel J
    Science; 2021 Nov; 374(6569):799-800. PubMed ID: 34762459
    [No Abstract]   [Full Text] [Related]  

  • 29. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study.
    Lai FTT; Wang B; Wei C; Chui CSL; Li X; Cheung CL; Wong ICK; Chan EWY; Wan EYF
    Age Ageing; 2024 Aug; 53(8):. PubMed ID: 39141078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness of Nirmatrelvir/Ritonavir on Coronavirus Disease 2019-Associated Hospitalization Prevention: A Population-based Cohort Study in the Province of Quebec, Canada.
    Kaboré JL; Laffont B; Diop M; Tardif MR; Turgeon AF; Dumaresq J; Luong ML; Cauchon M; Chapdelaine H; Claveau D; Brosseau M; Haddad E; Benigeri M
    Clin Infect Dis; 2023 Sep; 77(6):805-815. PubMed ID: 37149726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
    Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
    Jang YR; Oh Y; Kim JY
    J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation.
    Yan L; Bui D; Li Y; Rajeevan N; Rowneki M; Berry K; Argraves S; Huang Y; Hynes DM; Cunningham F; Huang GD; Aslan M; Ioannou GN; Bajema KL
    Clin Infect Dis; 2024 Sep; 79(3):643-651. PubMed ID: 38864601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
    Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
    Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
    Chagla Z
    Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
    Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
    Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.